{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:00:36Z","timestamp":1792047636351,"version":"4.4.0"},"reference-count":98,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1097\/01.cco.0000245317.82391.1b","type":"journal-article","created":{"date-parts":[[2006,9,21]],"date-time":"2006-09-21T04:12:12Z","timestamp":1158811932000},"page":"652-659","source":"Crossref","is-referenced-by-count":32,"title":["The changing scene of adult acute lymphoblastic leukemia"],"prefix":"10.1097","volume":"18","author":[{"given":"Antonella","family":"Vitale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Guarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Chiaretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20210128","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMra023001","article-title":"Acute lymphoblastic leukemia","volume":"350","author":"Pui","year":"2004","journal-title":"N Engl J Med"},{"key":"R2-18-20210128","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1200\/JCO.2005.05.047","article-title":"Molecular genetics of acute lymphoblastic leukemia","volume":"23","author":"Armstrong","year":"2005","journal-title":"J Clin Oncol"},{"key":"R3-18-20210128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2354.2005.00513.x","article-title":"A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL)","volume":"14","author":"Redaelli","year":"2005","journal-title":"Eur J Cancer Care"},{"key":"R4-18-20210128","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/aje\/kwi272","article-title":"Variation in the seasonal diagnosis of acute lymphoblastic leukemia: evidence from Singapore, the United States, and Sweden","volume":"162","author":"Gao","year":"2005","journal-title":"Am J Epidemiol"},{"key":"R5-18-20210128","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.critrevonc.2003.11.003","article-title":"Adult acute lymphoblastic leukaemia","volume":"50","author":"Bassan","year":"2004","journal-title":"Crit Rev Oncol Hematol"},{"key":"R6-18-20210128","first-page":"235","article-title":"Advances in acute lymphoblastic leukemia","volume":"17","author":"Randolf","year":"2004","journal-title":"Clin Lab Sci"},{"key":"R7-18-20210128","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1532\/IJH97.04137","article-title":"DNA microarrays in the diagnosis and management of acute lymphoblastic leukemia","volume":"80","author":"Ferrando","year":"2004","journal-title":"Int J Hematol"},{"key":"R8-18-20210128","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"Lu","year":"2005","journal-title":"Nature"},{"key":"R9-18-20210128","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4065\/80.11.1517","article-title":"Adult acute lymphoblastic leukemia","volume":"80","author":"Jabbour","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"R10-18-20210128","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1468-0734.2002.00070.x","article-title":"Towards an integrated classification of adult acute lymphoblastic leukemia","volume":"6","author":"Fo\u00e0","year":"2002","journal-title":"Rev Clin Exp Hematol"},{"key":"R11-18-20210128","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1046\/j.1468-0734.2002.00068.x","article-title":"Recent approaches in acute lymphoblastic leukemia in adults","volume":"6","author":"Gokbuget","year":"2002","journal-title":"Rev Clin Exp Hematol"},{"key":"R12-18-20210128","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"R13-18-20210128","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"key":"R14-18-20210128","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1182\/blood.V85.6.1416.bloodjournal8561416","article-title":"Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance","volume":"85","author":"Campana","year":"1995","journal-title":"Blood"},{"key":"R15-18-20210128","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000077554","article-title":"Minimal residual disease studies by flow cytometry in acute leukemia","volume":"112","author":"Campana","year":"2004","journal-title":"Acta Haematol"},{"key":"R16-18-20210128","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.1998.16.12.3774","article-title":"Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia","volume":"16","author":"Ciudad","year":"1998","journal-title":"J Clin Oncol"},{"key":"R17-18-20210128","first-page":"3931","article-title":"Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364","volume":"93","author":"Czuczman","year":"1999","journal-title":"Blood"},{"key":"R18-18-20210128","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1521-6926(03)00067-7","article-title":"Minimal residual disease monitoring by flow cytometry","volume":"16","author":"Vidriales","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"key":"R19-18-20210128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.imlet.2004.10.008","article-title":"Immunophenotyping of acute leukemias","volume":"98","author":"Bene","year":"2005","journal-title":"Immunol Lett"},{"key":"R20-18-20210128","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)","volume":"9","author":"Bene","year":"1995","journal-title":"Leukemia"},{"key":"R21-18-20210128","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00062752-200207000-00009","article-title":"Antibody-based therapy of human leukemia","volume":"9","author":"Nemecek","year":"2002","journal-title":"Curr Opin Hematol"},{"key":"R22-18-20210128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00277-003-0752-8","article-title":"Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects","volume":"83","author":"Gokbuget","year":"2004","journal-title":"Ann Hematol"},{"key":"R23-18-20210128","first-page":"3135","article-title":"A Collaborative Study of the Group Francais de Cytogenetique Hematologique.","volume":"87","year":"1996","journal-title":"Blood"},{"key":"R24-18-20210128","first-page":"3983","article-title":"Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience","volume":"93","author":"Wetzler","year":"1999","journal-title":"Blood"},{"key":"R25-18-20210128","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1468-0734.2002.00069.x","article-title":"Cytogenetics and molecular genetics of acute lymphoblastic leukemia","volume":"6","author":"Harrison","year":"2002","journal-title":"Rev Clin Exp Hematol"},{"key":"R26-18-20210128","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0037-1963(00)90018-0","article-title":"Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia","volume":"37","author":"Ferrando","year":"2000","journal-title":"Semin Hematol"},{"key":"R27-18-20210128","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1182\/blood-2004-07-2922","article-title":"A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol","volume":"105","author":"Mancini","year":"2005","journal-title":"Blood"},{"key":"R28-18-20210128","first-page":"275","article-title":"A multiplex reverse transcriptase-polymerase chain reaction strategy for the diagnostic molecular screening of chimeric genes: a clinical evaluation on 170 patients with acute lymphoblastic leukemia","volume":"88","author":"Elia","year":"2003","journal-title":"Haematologica"},{"key":"R29-18-20210128","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"17","author":"Van Dongen","year":"2003","journal-title":"Leukemia"},{"key":"R30-18-20210128","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/nrg1692","article-title":"The new cytogenetics: blurring the boundaries with molecular biology","volume":"6","author":"Speicher","year":"2005","journal-title":"Nat Rev Genet"},{"key":"R31-18-20210128","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2001-12-0371","article-title":"MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia","volume":"100","author":"Tafuri","year":"2002","journal-title":"Blood"},{"key":"R32-18-20210128","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mrfmmm.2005.02.030","article-title":"Multiple drug resistance, antimutagenesis and anticarcinogenesis","volume":"591","author":"Ferguson","year":"2005","journal-title":"Mutat Res"},{"key":"R33-18-20210128","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.1158\/1078-0432.CCR-05-1096","article-title":"Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia","volume":"11","author":"Plasschaert","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R34-18-20210128","first-page":"882","article-title":"Multidrug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia","volume":"57","author":"Jamroziak","year":"2005","journal-title":"Pharmacol Rep"},{"key":"R35-18-20210128","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ejca.2005.09.017","article-title":"Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia","volume":"42","author":"Swerts","year":"2006","journal-title":"Eur J Cancer"},{"key":"R36-18-20210128","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1126\/science.286.5439.531","article-title":"Molecular classification of cancer: class discovery and class prediction by gene expression monitoring","volume":"286","author":"Golub","year":"1999","journal-title":"Science"},{"key":"R37-18-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1535-6108(02)00018-1","article-title":"Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia","volume":"1","author":"Ferrando","year":"2002","journal-title":"Cancer Cell"},{"key":"R38-18-20210128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1535-6108(02)00032-6","article-title":"Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling","volume":"1","author":"Yeoh","year":"2002","journal-title":"Cancer Cell"},{"key":"R39-18-20210128","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood-2004-01-0274","article-title":"Genomic approaches to hematologic malignancies","volume":"104","author":"Ebert","year":"2004","journal-title":"Blood"},{"key":"R40-18-20210128","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2003-09-3243","article-title":"Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival","volume":"103","author":"Chiaretti","year":"2004","journal-title":"Blood"},{"key":"R41-18-20210128","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1158\/1078-0432.CCR-04-2165","article-title":"Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation","volume":"11","author":"Chiaretti","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R42-18-20210128","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2004-12-4938","article-title":"Global approach to the diagnosis of leukemia using gene expression profiling","volume":"106","author":"Haferlach","year":"2005","journal-title":"Blood"},{"key":"R43-18-20210128","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1182\/blood-2003-05-1518","article-title":"Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia","volume":"103","author":"Fine","year":"2004","journal-title":"Blood"},{"key":"R44-18-20210128","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2004-06-2498","article-title":"FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression","volume":"105","author":"Brown","year":"2005","journal-title":"Blood"},{"key":"R45-18-20210128","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.2002.20.4.1094","article-title":"Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia","volume":"20","author":"Mortuza","year":"2002","journal-title":"J Clin Oncol"},{"key":"R46-18-20210128","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1053\/beha.2002.0186","article-title":"Molecular analysis of minimal residual disease in adult acute lymphoblastic leukaemia","volume":"15","author":"Foroni","year":"2002","journal-title":"Best Pract Res Clin Haematol"},{"key":"R47-18-20210128","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/beha.2002.0229","article-title":"Risk-adapted treatment according to minimal residual disease in adult ALL","volume":"15","author":"Gokbuget","year":"2002","journal-title":"Best Pract Res Clin Haematol"},{"key":"R48-18-20210128","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Bruggemann","year":"2006","journal-title":"Blood"},{"key":"R49-18-20210128","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ajh.20461","article-title":"Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients","volume":"80","author":"Toubai","year":"2005","journal-title":"Am J Hematol"},{"key":"R50-18-20210128","first-page":"146","article-title":"Detection of minimal residual disease in acute leukemia","volume":"18","author":"Van der Velden","year":"2004","journal-title":"J Biol Regul Homeost Agents"},{"key":"R51-18-20210128","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1182\/blood-2002-08-2613","article-title":"Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value","volume":"101","author":"Vidriales","year":"2003","journal-title":"Blood"},{"key":"R52-18-20210128","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1365-2141.2003.03974.x","article-title":"Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia","volume":"120","author":"Krampera","year":"2003","journal-title":"Br J Haematol"},{"key":"R53-18-20210128","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/sj.leu.2403448","article-title":"Retrospective comparison of qualitative and quantitative reverse transcriptase polymerase chain reaction in diagnosing and monitoring the ALL1-AF4 fusion transcript in patients with acute lymphoblastic leukaemia","volume":"18","author":"Elia","year":"2004","journal-title":"Leukemia"},{"key":"R54-18-20210128","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.leu.2403683","article-title":"Significant reduction of the hybrid BCR\/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia","volume":"19","author":"Pane","year":"2005","journal-title":"Leukemia"},{"key":"R55-18-20210128","first-page":"1126","article-title":"Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements","volume":"87","author":"Gameiro","year":"2002","journal-title":"Haematologica"},{"key":"R56-18-20210128","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.leu.2403263","article-title":"Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia","volume":"18","author":"Bruggemann","year":"2004","journal-title":"Leukemia"},{"key":"R57-18-20210128","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","article-title":"Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis","volume":"99","author":"Gleissner","year":"2002","journal-title":"Blood"},{"key":"R58-18-20210128","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/blood-2004-09-3666","article-title":"Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study","volume":"105","author":"Asnafi","year":"2005","journal-title":"Blood"},{"key":"R59-18-20210128","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0889-8588(05)70191-X","article-title":"Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B","volume":"14","author":"Larson","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"R60-18-20210128","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"key":"R61-18-20210128","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukaemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"R62-18-20210128","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V99.3.863","article-title":"Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study","volume":"99","author":"Annino","year":"2002","journal-title":"Blood"},{"issue":"Suppl 1","key":"R63-18-20210128","first-page":"S129","article-title":"Risk\/MRD adapted GMALL trials in adult ALL","volume":"83","author":"Gokbuget","year":"2004","journal-title":"Ann Hematol"},{"key":"R64-18-20210128","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","article-title":"Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial","volume":"22","author":"Thomas","year":"2004","journal-title":"J Clin Oncol"},{"key":"R65-18-20210128","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"R66-18-20210128","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med"},{"key":"R67-18-20210128","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1182\/blood.V86.6.2091.bloodjournal8662091","article-title":"The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia","volume":"86","author":"Cortes","year":"1995","journal-title":"Blood"},{"key":"R70-18-20210128","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1182\/blood-2003-10-3560","article-title":"Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial","volume":"104","author":"Hunault","year":"2004","journal-title":"Blood"},{"key":"R71-18-20210128","first-page":"1346","article-title":"Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as postremission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial","volume":"90","author":"Ribera","year":"2005","journal-title":"Haematologica"},{"key":"R72-18-20210128","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.leu.2404065","article-title":"Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85-87 and -94 trials","volume":"20","author":"Dhedin","year":"2006","journal-title":"Leukemia"},{"key":"R73-18-20210128","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.bmt.1705370","article-title":"Autologous stem cell transplant in ALL: who should we be transplanting in first remission?","volume":"37","author":"Mato","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"R74-18-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbmt.2005.10.018","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review","volume":"12","author":"Hahn","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"R75-18-20210128","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1056\/NEJMoa041469","article-title":"Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia","volume":"351","author":"Rocha","year":"2004","journal-title":"N Engl J Med"},{"key":"R76-18-20210128","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa041276","article-title":"Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia","volume":"351","author":"Laughlin","year":"2004","journal-title":"N Engl J Med"},{"key":"R77-18-20210128","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted cancer therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nature"},{"key":"R78-18-20210128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrc1800","article-title":"Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy","volume":"6","author":"Cheok","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"R79-18-20210128","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s00277-003-0728-8","article-title":"A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+\/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)","volume":"82","author":"Wassmann","year":"2003","journal-title":"Ann Hematol"},{"key":"R80-18-20210128","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood-2004-09-3785","article-title":"The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"105","author":"Lee","year":"2005","journal-title":"Blood"},{"key":"R81-18-20210128","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group","volume":"24","author":"Yanada","year":"2006","journal-title":"J Clin Oncol"},{"key":"R83-18-20210128","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"R84-18-20210128","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"R85-18-20210128","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"key":"R87-18-20210128","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"R88-18-20210128","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"R89-18-20210128","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1200\/JCO.2005.09.005","article-title":"Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes","volume":"23","author":"Cortes","year":"2005","journal-title":"J Clin Oncol"},{"key":"R90-18-20210128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.2005.05556.x","article-title":"FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia","volume":"130","author":"Torelli","year":"2005","journal-title":"Br J Haematol"},{"key":"R91-18-20210128","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1046\/j.1365-2141.2003.04707.x","article-title":"Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study","volume":"123","author":"Rosen","year":"2003","journal-title":"Br J Haematol"},{"key":"R92-18-20210128","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1200\/JCO.2004.01.046","article-title":"Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis","volume":"22","author":"Bomgaars","year":"2004","journal-title":"J Clin Oncol"},{"key":"R93-18-20210128","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cncr.21005","article-title":"The role of clofarabine in hematologic and solid malignancies \u2013 development of a next-generation nucleoside analog","volume":"103","author":"Faderl","year":"2005","journal-title":"Cancer"},{"key":"R94-18-20210128","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2004-05-1933","article-title":"Results of a phase 1\u20132 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias","volume":"105","author":"Faderl","year":"2005","journal-title":"Blood"},{"key":"R95-18-20210128","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1517\/14656566.6.15.2711","article-title":"Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review","volume":"6","author":"Kline","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"R96-18-20210128","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2005.03.199","article-title":"Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies","volume":"23","author":"Kurtzberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"R97-18-20210128","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"R98-18-20210128","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1038\/sj.leu.2403930","article-title":"Antigen-specific cellular immunotherapy of leukemia","volume":"19","author":"Van Driessche","year":"2005","journal-title":"Leukemia"},{"key":"R100-18-20210128","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials","volume":"21","author":"Boissel","year":"2003","journal-title":"J Clin Oncol"},{"key":"R101-18-20210128","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2403538","article-title":"Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands","volume":"18","author":"De Bont","year":"2004","journal-title":"Leukemia"},{"key":"R103-18-20210128","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2141.2005.05544.x","article-title":"Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia","volume":"130","author":"Nachman","year":"2005","journal-title":"Br J Haematol"},{"key":"R104-18-20210128","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2003.11.116","article-title":"Difference in outcome in adolecent with acute lymphoblastic leukemia: a consequence of better regimes? Better doctors? Both?","volume":"21","author":"Schiffer","year":"2003","journal-title":"J Clinic Oncol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.cco.0000245317.82391.1b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:12:19Z","timestamp":1785859939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-200611000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.cco.0000245317.82391.1b","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}